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Endoplasmic reticulum (ER) is the cellular compartment where secreted and integral membrane proteins are folded
and matured. The accumulation of unfolded or misfolded proteins triggers a stress that is physiologically controlled
by an adaptative protective response called Unfolded Protein Response (UPR). UPR is primordial to induce a quality
control response and to restore ER homeostasis. When this adaptative response is defective, protein aggregates
overwhelm cells and affect, among other mechanisms, synaptic function, signaling transduction and cell survival.
Such dysfunction likely contributes to several neurodegenerative diseases that are indeed characterized by
exacerbated protein aggregation, protein folding impairment, increased ER stress and UPR activation. This review
briefly documents various aspects of the biology of the transcription factor XBP-1 (X-box Binding Protein-1) and
summarizes recent findings concerning its putative contribution to the altered UPR response observed in various
neurodegenerative disorders including Parkinson’s and Alzheimer’s diseases.
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Endoplasmic Reticulum (ER) is the compartment where
transmembrane and secreted proteins transit to be
matured and properly folded before routing to their final
location. Function and homeostasis of this structure are
crucial for cell fate. When ER is subjected to a stress, a
protein overload or any dysfunction, an adaptative re-
sponse, called Unfolded Protein Response (UPR) is initi-
ated in order to restore ER homeostasis (for review see
[1,2]). UPR failure results in the activation of an apoptosis-
dependent cell death. The UPR activates the transcription
of several genes that are involved in the reduction of pro-
tein synthesis as well as in the chaperoning and degradation
of misfolded or unfolded proteins. Such process involves
interplay between distinct signaling pathways mediated by
several transmembrane sensors, namely PKR-like ER kinase
(PERK), Activating Transcription Factor 6 (ATF-6) and
Inositol Requiring Enzyme 1 alpha (IRE1α). The most
conserved of these pathways implies the activation of
IRE1α, a Ser/Thr protein kinase that also harbors an* Correspondence: checler@ipmc.cnrs.fr
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unless otherwise stated.endoribonuclease activity. Once autoactivated, IRE1α in-
duces an unconventional splicing of the mRNA encoding
the X-box Binding Protein-1 (XBP-1) transcription factor,
which subsequently regulates the transcription of genes
involved in ER homeostasis. Recent studies have delineated
novel XBP-1 target genes and have documented additional
ER stress- and UPR- independent functions. Here we first
briefly describe some aspects of XBP-1 biology and report
on the experimental clues of its implication in various
metabolic and inflammatory disorders as well as in several
pathologies including cancer and neurodegenerative dis-
eases such as amyotrophic lateral sclerosis, Huntington’s,
Parkinson’s and Alzheimer’s diseases.X-box binding-protein 1 discovery
XBP-1 has been first described more than two decades
ago by the group of Dr Laurie Glimcher who worked on
MHC class II genes regulation [3]. Her group discovered
and characterized XBP-1 as a new member of the basic
region leucine zipper protein family (bZIP). This family
of transcription factors is involved in a wide spectrum of
physiological and pathological functions. Interestingly in
yeast, hac-1 that belongs to the bZIP family, contributes
to UPR activation in response to environmental stressLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Dunys et al. Molecular Neurodegeneration 2014, 9:35 Page 2 of 8
http://www.molecularneurodegeneration.com/content/9/1/35[4,5]. In eucaryotic cells, endoplasmic reticulum stress is
coupled to the splicing and thereby, activation of XBP-1
that appears as the mammalian counterpart of hac-1 [6].
XBP-1 is activated by an unconventional splicing
mechanism
XBP-1u (unspliced) mRNA is produced constitutively and
yields a protein that is rapidly degraded in physiological
conditions by the proteasome machinery [7]. When ER
stress occurs, the IRE1α kinase is activated through
autophosphorylation and acts as a stress sensor and trans-
ducer. IRE1α endoribonuclease activity then removes a 26
nucleotides intron from XBP-1u mRNA coding sequence
inducing a frame shift [8,9]. Thereafter, subsequent proc-
essed mRNA is translated onto a more stable 376 amino
acids-long isoform XBP-1s (spliced), which bears the
transcriptional activity (Figure 1).
This unconventional splicing mechanism is commonly
triggered by misfolded proteins overload but not only.
Dysregulations in lipid biosynthesis also induce an ER
stress response. IRE1α is able to appreciate imbalance in
membrane lipid composition and membrane fluidity
modulation. In such conditions, after homodimerization
and autophosphorylation, IRE1α activates the unconven-
tional XBP-1 mRNA splicing inducing transcription of
genes implicated in lipid biogenesis. Moreover, it is
interesting to note that UPR regulates transcription of
genes involved in the lipid biosynthetic pathways [10].Figure 1 Unconventional splicing of XBP-1. Xbp-1 gene is constitutively
resulting mRNA (U, panel B) contains a 26 nucleotides long intron that is t
(U, panel C). Upon ER stress, IRE1 autoactivates and triggers an unconventi
lower molecular weight of the semi quantitative PCR fragment (S, panel B)
of XBP-1, see panel A) but results in a modified reading frame resulting inBeside its effect on XBP-1 splicing-dependent activa-
tion, IRE-1α can process and/or degrade several other
mRNAs and miRNAs through a mechanism called RIDD
(Regulated IRE1α Dependent Decay) [11]. IRE1α also con-
tributes in additional cellular pathways through mecha-
nisms that do not involve its endoribonuclease activity but
its kinase activity.
XBP-1 function in multiple signaling pathways and diseases
Mammalian XBP-1 protein is widely expressed in adult
tissues and has a major role in development. The ques-
tion of XBP-1 function was addressed by examining the
contribution of its endogenous counterpart in mice
knock-out model [12]. Unfortunately, the homozygous
knock-out is lethal by day 10.5 to 14.5 in utero while
heterozygotes did not develop any defect. This prema-
ture lethality is explained by heart dysfunction due to an
acute cellular necrosis of cardiac myocytes.
Another developmental function of XBP-1 concerns
transition of mature B cells to antibody-secreting plasma
cells. XBP-1 transcripts are upregulated by stimuli indu-
cing plasma cell differentiation [13]. XBP-1 expression is
driven by IgM production and enhances immunoglobu-
lin secretion [14]. More largely, XBP-1 is involved in the
development of secretory tissues. Its transcriptional ac-
tivity is essential for hepatocyte growth. Thus, aside their
growth retardation, XBP-1−/− embryos develop hypo-
plastic livers [15]. At the adulthood, XBP-1 conditionaltranscribed into a mature mRNA (hXBP-1Unspliced; panel A) The
ranslated into an unstable and short 261 amino acids-long protein
onal excision of the 26 nucleotides long intron. This splicing results in a
yielded by primers a and b used for PCR (flanking the splicing region
a longer protein (S, panel C).
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lates genes implicated in hepatic lipogenesis [16].
ER stress and defects in the UPR adaptative response
have been linked to a high number of pathologies such as
metabolic disorders, immune and inflammatory diseases,
cardiovascular pathologies, cancers, and brain disorders
(Table 1). Moreover, XBP-1 has a growing number of
targets and functions related more or less to its role in ER-
stress regulation. Transcriptional targets of XBP-1s already
include genes implicated in support of ER function i.e. ER
chaperones such as the Protein Disulfide Isomerase (PDI)
[17], GRP78 BiP co-chaperone, Erdj4 [18], ERAD compo-
nents such as the E3 ubiquitin ligase HRD1 [19] or C/EBP
alpha which is an inducer of adipogenesis [20]. Other
more unexpected targets connect spliced XBP-1 to DNA
damage and repair pathways, myodegenerative and neuro-
degenerative diseases [21]. XBP-1s binding site contains a
consensus sequence consisting of an ACGT motif [18].
XBP-1 in metabolic disorders
Several lines of evidence suggest that obesity and type-2
diabetes share cellular conditions that trigger ER stress.
Pharmacological stimulation of ER stress in liver cells in-
hibits insulin action [22]. Mice developing a diet-induced
obesity present an increase in ER stress dependent XBP-1
splicing. Moreover, XBP-1 signaling is involved in insulin
sensitivity since XBP-1+/− mice present glucose homeosta-
sis impairment and are more susceptible to develop a
diet-induced insulin resistance.
At the molecular level, two different studies recently
brought explanations linking ER stress and PI3K pathwayTable 1 Evidences of XBP-1 implication in multiple pathologi
Pathologies Evidence
Metabolic disorders
- Diabetes XBP-1 influences gluc
- Non-alcoholic fatty liver disease XBP-1/PDI/MTP axis a
TLR4 dependent XBP
Inflammatory diseases
- Rheumatoid arthritis XBP-1 upregulation
- Inflammatory bowel disease XBP-1 gene single-nu
Cancers
- Lymphoid malignancies XBP-1 inhibition redu
- Breast cancers Activation of UPR and
- Colorectal cancers XBP-1 overexpression
Neurodegenerative diseases
- Huntington’s disease XBP-1 invalidation pro
- Alzheimer’s disease XBP-1 overexpression
XBP-1 polymorphism
- Parkinson’s disease Implication of IRE1-XB
- Amyotrophic lateral sclerosis Increase in XBP-1 splithrough XBP-1 nuclear translocation mechanism [44,45].
Insulin signaling disrupts the complex between two sub-
units of the Phosphatidylinositol-4,5-bisphosphate 3-kinase
(PI3K), p85α and p85β, and induces the formation of an
heterodimer complex between these subunits and XBP-1s.
Formation of this heterodimer allows XBP-1 nuclear
translocation.
Interestingly, XBP-1 also regulates glucose homeosta-
sis through transcription independent mechanism [23].
An XBP-1s mutant defective for DNA binding is able to
increase glucose tolerance. Spliced and activated XBP-1
isoform (XBP-1s) induces proteasomal degradation of
Forkhead box O1 (FoxO1), thus highlighting for the first
time a function of XBP-1 independent of its transcrip-
tional activity [23,46].
XBP-1 in inflammatory diseases
Discovery of several single-nucleotide polymorphisms on
XBP-1 gene related to inflammatory bowel disease (IBD)
has pointed out a link between ER stress and tissue
specific inflammatory pathologies [28]. Intestinal-specific
XBP-1 invalidation results in a defective antimicrobial
response as well as ER stress induction and inflamma-
tory response.
It has been postulated that XBP-1 could be activated
independently of ER stress, UPR mechanism and IRE1α
activation, through the Toll-Like Receptor (TLR) path-
way. This pathway is primordial for cytokine secretion
and has been described in synovial fibroblasts of patients
suffering from active rheumatoid arthritis, a joint inflam-




-1 activation by HFHC diet [26]
[27]
cleotide polymorphisms [28]
ces leukemic progression [29]
upregulation of XBP-1 [30-32]
in adenomas and adenocarcinomas [33]
tects over HD [34]
in AD patients [35-37]
associated to AD risk [38]
P-1 in dopaminergic neurons survival [39-41]
cing in ALS models [42,43]
Dunys et al. Molecular Neurodegeneration 2014, 9:35 Page 4 of 8
http://www.molecularneurodegeneration.com/content/9/1/35synovial fibroblasts of Rheumatoid Arthritis (RA) pa-
tients, other UPR markers were largely down-regulated,
suggesting the uncoupling between the two signaling
pathways. Two TLR isoforms, TLR4 and TLR2, induce
production of pro-inflammatory cytokines such as tumor
necrosis factor alpha (TNFα) and interleukine-6 (IL-6).
In turn, TNFα potentiates XBP-1 splicing therefore
holding a positive feedback loop [27].XBP-1 in cancer
XBP-1 is expressed ubiquitously and is increased in
many types of cancers as is the case for several down-
stream targets of UPR. The pathways through which
IRE1α/XBP-1 branch is involved in progression of differ-
ent cancers is still unknown and few hypotheses begin to
emerge. XBP-1 transcription factor is implicated in a
number of pathways related to tumorigenicity, such as
apoptosis and mitochondrial permeability, drug resistance
and drug induced cell cycle arrest (for review see [47]).
Moreover, decrease in XBP-1 expression appears to
potentiate cell sensitivity to hypoxia. The IRE1α-XBP-1
branch of the UPR has been implicated in regulation of
proliferation through the modulation of cyclin A1 [48].
The role of XBP-1 in progression of mammary epithe-
lial cell cancer has recently been investigated. XBP-1
transcriptional activity drives Triple-Negative Breast
Cancer (TNBC) tumorigenicity and activation of the tran-
scription factor is correlated with a poor prognosis [30].
XBP-1 silencing triggers an inhibition of cell growth and
tumor invasiveness. The mechanism of XBP-1 implication
in TNBC progression involves interaction with another
transcription factor, HIF-1α [30].
One of the developmental functions of XBP-1 con-
cerns B cell differentiation [13]. Paradoxically, XBP-1 ap-
pears to intervene also in chronic lymphocytic leukemia,
since XBP-1 inhibition interferes with leukemia cells and
lymphoma survival [29].
Overall, many studies bring together evidences point-
ing out that XBP-1 is of particular interest regarding its
potential as an anti-cancer therapeutic target.XBP-1 in neurodegenerative diseases
The accumulation and aggregation of misfolded proteins
is a common feature for neurodegenerative disorders.
Those aggregates are harmful for neurons and lead to
activation of UPR signaling pathways in order to restore
ER homeostasis. However, when the UPR process fails in
this task, a prolonged ER stress could trigger neuronal cell
death as it is the case in several neurodegenerative
diseases. The IRE1α/XBP-1 branch of UPR has been
implicated in several neurodegenerative disorders, some of
which are developed hereafter.XBP-1 in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a dramatic and lethal
adult-onset degenerative disease characterized by muscular
weakness, atrophy and paralysis due to brain stem, spinal
cord, cortico-spinal tract, primary motor cortex motoneu-
rons neurodegeneration and degradation of the neuromus-
cular junctions [49]. Several data incriminate ER stress and
aggregation of misfolded proteins in ALS etiology.
Rodents expressing mutations in the SOD1 gene,
which is involved in genetic familial cases of ALS, show
an activation of the three branches of the UPR and an
increase in the IRE1α dependent unconventional splicing
of XBP-1 mRNA [42]. Unexpectedly, selective deficiency
of XBP-1 in the nervous system of a rodent model of
familial ALS triggers a decrease in SOD1 accumulation
through an autophagy-dependent mechanism, which
induces motoneurons survival [43].
XBP-1 in Huntington’s disease
Huntington’s disease (HD) is an inherited genetic disorder
that progressively causes nerve cell degeneration. The
dominant genetic alteration is a CAG trinucleotide repeat
in the IT15 gene leading to the expression of an expanded
polyglutamine (polyQ) track at the N-terminus of the
Huntingtin protein (Htt) [50,51]. The length of this polyQ
motif, which usually does not exceed 40 glutamines in
healthy persons, is correlated to the severity of the
pathology [52]. Moreover, the number of polyglutamine
repeats drives the propensity of Htt to aggregate. Folding
abnormalities are common in trinucleotide repeat disor-
ders and often linked to neuronal cell death. Polygluta-
mines expansions on mutant Htt protein impair several
physiological functions of the protein. The question of the
role of the Htt aggregates in the pathology – are they a
cause or a consequence – remains to be determined.
However, ER stress and UPR activation have been re-
ported in HD models and markers of these two pathways
have been found after post-mortem analysis of HD pa-
tient’s brains [34,53]. Moreover, polyglutaminated mutant
Htt appears to inhibit ERAD process therefore enhancing
ER stress induced apoptosis [54].
Literature offers contrasting results about the implica-
tion of XBP-1 in aggregation of mutant Htt. On the one
hand, an increase in XBP-1 mRNA unconventional spli-
cing has been noticed in transgenic animals that express
a mutant Htt. In addition, conditional XBP-1 deficient
mice appear to be less prone to develop the pathology
and present less neuronal cell death and reduced motor
deficits [34]. Interestingly in this study, XBP-1 implica-
tion in Huntington’s disease seems to be independent of
its function in ER stress regulation. XBP-1 depletion
tends here to influence mutant Htt degradation through
an autophagy dependent mechanism [34]. On another
hand, a study performed in adult mice through adeno-
Dunys et al. Molecular Neurodegeneration 2014, 9:35 Page 5 of 8
http://www.molecularneurodegeneration.com/content/9/1/35associated viral (AAV) specific delivery into striatum of
an active form of XBP-1 showed a reduction of Htt
aggregation and inclusions formation [55].
XBP-1 in Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form of
age-related dementia worldwide. The pathology is char-
acterized by two morphological stigmata: senile plaques
consisting of extracellular aggregates mainly composed
of a set of amyloid-beta-related peptides (Aβ) and neuro-
fibrillary tangles that are intracellular aggregates of a
hyperphosphorylated protein, the microtubule associated
protein Tau. These two histopathological markers are
accompanied by oxidative stress, neuroinflammation,
synaptic deficits and neuronal cell death.
Several studies have suggested an induction of ER stress
and an activation of UPR signaling pathways in Alzheimer’s
disease [56]. Increases in markers such as GRP78 and
phospho-PERK have been described in cortex and hippo-
campus of AD patients [57,58]. In familial genetic cases of
AD, ER stress induction and UPR attenuation have been
described [59] while in sporadic cases of the pathology, ER
stress is due to a reduction in Protein Disulfide Isomerase
(PDI) activity [60]. However, such ER stress activation has
not been recovered in aged Tg2576 mice, a transgenic
mouse model that develops plaques and synaptic failures
but lack the Tau dependent counterpart of the pathology
[37]. XBP-1 mRNA unconventional splicing appears to be
increased in the cortex of AD patients as well as PDI
expression [37]. Moreover, it has been suggested that the
polymorphism -116C/G of XBP-1 gene could increase the
susceptibility to develop Alzheimer’s disease in a Chinese
population [38].
XBP-1 spliced isoform has been shown to mediate
protective effects against amyloid-β peptide and amyloid
oligomers induced toxicity [35]. Therefore, XBP-1s tends
to impair cytoplasmic calcium accumulation through the
regulation of ryanodine calcium channel RyR3. Interest-
ingly, XBP-1 unconventional splicing was potentiated by
amyloid-β peptide and Aβ oligomers in mammalian neu-
rons cultures as well as in drosophila neurons suggesting a
highly conserved mechanism [35].
Recently, a screening approach carried out in order to
identify transcription factors implicated in regulation of two
secretases involved in the amyloid precursor protein (APP)
processing pathways, ADAM10 (A Disintegrin And Metal-
loproteinase 10) and BACE1 (βAPP Cleaving Enzyme 1)
[61] pointed out the entailment of XBP-1 in ADAM10
regulation. Thus, this study revealed that XBP-1s is induced
at an early time point in two transgenic mouse models
mimicking in part the pathology [36]. ADAM10 expression
is transcriptionally modulated by XBP-1 in neuronal cells
and such modulation can be achieved by pharmacological
induction of ER stress [36].One of the transcriptional targets of XBP-1 during ER
stress is the protein HRD1 which is involved in ERAD
process. HRD1 expression has been found consequently
diminished in AD brains [62]. Interestingly, HRD1 binds
to APP and promotes its ubiquitination and subsequent
proteasomal degradation. Therefore in addition to its role
on ADAM10 expression and through activation of HRD1
and degradation of APP, XBP-1 indirectly modulates
amyloid-β production.
XBP-1 in Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by specific death of dopaminergic neurons
of the substantia nigra pars compacta (SNpc). At the
histological level, affected neurons present intraneuronal
inclusions, called Lewy bodies that are composed pre-
dominantly of aggregated α-synuclein protein.
Involvement of ER stress and UPR activation in Par-
kinson’s disease has been described in pharmacological
models of the pathology [63] as well as in patient’s brain
[64]. Moreover, characteristic defaults found in PD
models such as mitochondrial dysfunction, protein mis-
folding, protein aggregation and degradation impairment
are known to trigger ER stress. However, contribution of
ER stress to the disease is not very well understood but
several studies have examined this possibility. In human
brains, UPR activation has been investigated in the substan-
tia nigra. It appeared that neurons containing high concen-
tration of α-synuclein were also positive for phospho-PERK
and PD patient’s brain present an activation of the PERK-
eIF2α pathway of the UPR [64].
The implication of a second branch of the UPR in
dopaminergic neurons survival has been examined. The
IRE1α-XBP-1s dependent pathway was activated in a
model of specific dopaminergic neurodegeneration in-
duced by MPTP (1-methyl-4-phenyl-1.2.3.6-tetrahydro-
pyridine) [65]. Adenoviral mediated expression of XBP-
1s in MPTP-treated mice tend to foil dopaminergic neu-
rons death, suggesting that XBP-1s has protective effects
against PD mimetic insults. Another study confirmed
XBP-1 protective effects and published recently similar
observations. Local stereotaxic delivery of XBP-1s in the
substantia nigra induces a neuroprotection against 6-
hydroxydopamine (6-OHDA) exposure [39]. Moreover,
selective invalidation of XBP-1 in dopaminergic neurons
of the substantia nigra pars compacta triggers chronic
ER stress and neurodegeneration of the neurons targeted
[39]. It has also been postulated that α-synuclein aggre-
gates promote XBP-1 splicing and activation in human
neuroblastoma [41].
We have recently uncovered a novel transcriptional
target of XBP-1s, the protein DJ-1 [40]. Mutations on
DJ-1 gene (Park7) have been associated with autosomal
recessive early-onset forms of the disease [66]. We first
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parkin (PK) another protein involved in familial recessive
cases of PD. Parkin, which has been largely studied for
its role as an E3-ubiquitin ligase [67] possesses another
function as a transcription factor [68,69]. Thus, we
established that parkin represses the transactivation of
the p53 promoter [68]. Interestingly we showed that p53
acts as an upstream negative regulator of XBP-1 [40].
Furthermore, we identified a XBP-1 consensus binding
motif within the DJ-1 promoter sequence that is con-
served in several species. Overall, our data suggested
that parkin could control DJ-1 expression through a
cascade involving two intermediates transcription factors
p53 and XBP-1 [70]. Moreover, we have shown that this
indirect control of DJ-1 by parkin can be abrogated
by autosomal recessive parkin mutations implicated in
familial cases of PD [40].
Altogether, these different studies suggest that target-
ing the UPR and for example modulating XBP-1s ex-
pression through gene transfer may have therapeutic
potential benefits in order to treat Parkinson’s disease.
Conclusion
Regulation of ER homeostasis is a key feature in several
pathological conditions. When UPR fails to buffer ER stress
imbalance, it turns out to induce cell death. This point is
critical in neurodegenerative diseases since neuronal cell
death is highly detrimental. XBP-1 has important implica-
tions in ER stress induced transcriptional regulations.
It has been pointed out that XBP-1 could also have
functions in modulation of metabolism, inflammation or
lipogenesis in a transcription factor independent manner.
In some neurodegenerative disorders, XBP-1 implication
is also independent of ER stress and UPR activation.
Overall, XBP-1 appears as a pleiotropic transcription factor
regulating a wide set of proteins involved in various func-
tions linked to or independent of UPR and ER stress and
therefore, could be seen as a putative target of therapeutic
strategies aimed at interfering with distinct pathologies.
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